ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 
Gold Prices Drop as Strong Dollar, Rising U.S.-Iran Tensions Weigh on Market Sentiment 
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic 
Woodside Energy Acquires PetroChina’s Browse Stake, Expands Position in Major Australian Gas Project 
EngineAI Files for Hong Kong IPO Amid Rising Demand for AI and Robotics Stocks 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
Pakistan Economy Grows 3.7% in FY2026 Amid Strong Fiscal Performance 
Japan Core Inflation Seen Steady in May Ahead of BOJ Rate Hike 
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally 
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges 
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal 
Gold Prices Slip Weekly Despite Friday Rebound as U.S.-Iran Peace Deal Hopes Grow 
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion 
Asian Stocks Surge as Middle East Peace Hopes Lift Markets; SpaceX IPO Shatters Records 
Samsung Biologics contradicted reports that it will be producing Pfizer’s coronavirus vaccine. There were news going around saying the South Korean biotechnology company headquartered in Incheon is set to start the production of the said American pharmaceutical corp’s COVID-19 vaccine soon.
False manufacturing deal report?
As per The Korea Herald, Samsung Biologics said that the report that was published by the Korea Economic Daily was “not factual.” In the report, it was claimed that the Korean firm is in talks with Pfizer for a manufacturing deal.
An unnamed source from the government allegedly said, “If all goes well, the company will be able to begin mass production of the vaccine in August at the earliest.”
However, Samsung Biologics is saying there is no such deal and not even a discussion about any contract to produce the vaccines for Pfizer. Besides, the American pharma company does not appear to have a problem in producing huge amounts of vaccine doses by itself.
In fact, Bloomberg reported just last week that Pfizer and BioNTech can produce as many as 3 billion doses of their coronavirus vaccine in this year alone. This is said to be more than double the number that the company’s partners had predicted six months ago.
What’s more, Pfizer and BioNTech are reportedly further increasing their production capacity for next year. They are aiming to manufacture more than 3 billion vials of the vaccine. The boost in production comes as the demand has also surged around the world.
Pfizer also deny production outside of its manufacturing lines
It was reported that Pfizer is exclusively manufacturing its own vaccine in its two dedicated supply lines located in Europe and the U.S. The doses made here are for global distribution.
“At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine,” Pfizer said. “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available.”
Meanwhile, South Korea is one of the countries that are waiting for deliveries of Pfizer vaccines. It was said that the Korean government has a contract with the vaccine maker for the supply of 66 million doses of its COVID-19 vaccine.
